Characteristics of patients with a work assessment in the pre-pandemic year
| Variable | Total (n=204) |
| Age, years | 50.8 (10.7) |
| Male, n (%) | 97 (47.6) |
| High education, n (%) | 97 (47.6) |
| Employed, n (%) | 126 (61.8) |
| Current/former smoker, n (%) | 87 (42.9) |
| Diagnosis, n (%) | |
| axSpA | 109 (54.5) |
| pSpA | 23 (11.5) |
| PsA | 62 (31.0) |
| IBD-associated SpA | 3 (1.5) |
| uSpA | 3 (1.5) |
| Uveitis (ever), n (%) | 33 (16.5) |
| IBD (ever), n (%) | 25 (12.5) |
| Psoriasis (ever), n (%) | 84 (42.0) |
| ASDAS | 2.2 (1.0) |
| BASDAI (0–10) | 4.2 (2.4) |
| Patient global assessment | 4.0 (2.8) |
| Current medication use, n (%) | |
| NSAID | 115 (56.4) |
| csDMARD | 69 (33.8) |
| bDMARD | 120 (58.8) |
| tsDMARD | 2 (1.0) |
Values are mean (SD), unless stated otherwise.
ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; pSpA, peripheral spondyloarthritis; SpA, spondyloarthritis; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.